Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

107.17
-5.3600-4.76%
Post-market: 107.170.00000.00%19:30 EDT
Volume:441.21K
Turnover:47.60M
Market Cap:7.38B
PE:-34.38
High:114.75
Open:110.21
Low:107.09
Close:112.53
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:1.13
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:71.65
PE(LYR):-34.46

Loading ...

Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
May 08

Rhythm Pharmaceuticals price target raised to $143 from $140 at Canaccord

TIPRANKS
·
May 08

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results

Benzinga Earnings
·
May 07

Rhythm Pharma CEO joins Bank of America Global Healthcare Conference fireside chat

Reuters
·
May 06

Rhythm Pharmaceuticals (RYTM) Receives a Buy from Guggenheim

TIPRANKS
·
May 06

BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel

Reuters
·
May 06

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Viridian Therapeutics (VRDN)

TIPRANKS
·
May 06

Stock Track | Rhythm Pharmaceuticals Soars 12.79% Intraday on Better-Than-Expected Q1 Results Driven by IMCIVREE Launch

Stock Track
·
May 05

Rhythm Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

Rhythm Pharmaceuticals Shares up 7.5% Premarket After Q1 Revenue Rises

THOMSON REUTERS
·
May 05

Rhythm Pharmaceuticals Q1 revenue rises 84%

Reuters
·
May 05

Rhythm Q1 FY26 net loss widens to $56.7 million; revenue rises to $60.1 million

Reuters
·
May 05

Stock Track | Rhythm Pharmaceuticals Soars 9.84% in Pre-market on Better-Than-Expected Q1 Results

Stock Track
·
May 05

Rhythm Pharmaceuticals Q1 EPS $(0.83) Beats $(0.84) Estimate, Sales $60.112M Beat $55.776M Estimate

Benzinga Earnings
·
May 05

BRIEF-Rhythm Pharmaceuticals Q1 Net Income USD -55.639 Million Vs. IBES Estimate USD -55.3 Million

Reuters
·
May 05

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

THOMSON REUTERS
·
May 05

Rhythm Pharmaceuticals presents Phase 3 TRANSCEND trial data

TIPRANKS
·
May 04

BRIEF-Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society

Reuters
·
May 04

Rhythm presents 2.5-year setmelanotide data in pediatric acquired hypothalamic obesity trial

Reuters
·
May 04

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

THOMSON REUTERS
·
May 04